ArticleJBMR plus2025
Pain and physical function affecting quality of life in patients with osteogenesis imperfecta, X-linked hypophosphatemia, and hypermobile Ehlers-Danlos syndrome.
Article in JBMR plus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dose matters: haploinsufficiency in osteogenesis imperfecta.Nature reviews. Endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hereditary musculoskeletal disorders, including OI, X-linked hypophosphatemia (XLH), and hypermobile Ehlers-Danlos syndrome (hEDS), are associated with significantly diminished quality of life (QoL) compared to the general population. Although the recognition of patient-reported outcomes (PROs) in clinical practice is growing, the specific factors that most profoundly influence QoL in these disorders, as well as the differences among them, remain poorly understood. The objective of this cross-sectional study was to examine the QoL in 142 adult patients with rare genetic disorders, focusing on pain intensity and pain-related limitations. Medical data from patient records were collected and analyzed statistically. QoL was assessed using generic questionnaires (BPI-SF, EQ-5D-5L, SF-36v2), and pain intensity along with related limitations were evaluated. The data were analyzed using SPSS software, with regression analyses conducted to identify factors associated with QoL. All patient groups reported pain, which was associated with a significantly reduced QoL. Among these groups, those with hEDS experienced the most severe impairment and reported the highest levels of pain. Meanwhile, patients with OI type III faced the most substantial limitations in physical functioning, whereas no significant differences could be found between OI type I and XLH. To improve overall QoL for individuals with OI, XLH, and hEDS, it is essential to implement multimodal pain management strategies, addressing not only physical pain but also psychological and social dimensions. Additionally, ongoing development and integration of PROs into clinical practice will enhance the understanding of how these conditions affect patients, guiding the creation of more effective, patient-centered interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.